Drugs / TIL-TCM
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05438797 | Apr 2021 → Apr 2024 | digestive system cancer | Sizhen Wang | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TIL-TCM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05438797 ↗ |
| Modality | Cell therapy | “TIL-TCM cells are isolated from the patients' Tumor tissue (or ascites) and peripheral blood obtained before standard chemotherapy and then cultured ex-vivo.” NCT05438797 ↗ |